Search results
Merit Financial Group LLC Lowers Stock Holdings in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 5 days agoMerit Financial Group LLC lowered its position in Moderna, Inc. (NASDAQ:MRNA – Free Report) by 19.1% in the 4th quarter, according to its most recent 13F filing with the SEC ...
Company News For May 13, 2024
Zacks via Yahoo Finance· 19 hours agoNovavax, Inc. (NVAX) shares surged 98.7% after announcing a $1.2 billion deal with Sanofi (SNY) to commercialize a combined COVID-19 and flu vaccine. ...
Metis Global Partners LLC Trims Stock Position in Moderna, Inc. (NASDAQ:MRNA)
ETF DAILY NEWS· 5 days agoMetis Global Partners LLC reduced its stake in shares of Moderna, Inc. (NASDAQ:MRNA – Free Report) by 19.9% during the fourth quarter, according to the company in its most ...
Moderna Stock Slips as FDA Delays RSV Vaccine Approval
Investopedia· 4 days agoModerna (MRNA) shares lost ground in intraday trading Friday as the biotech’s effort to move beyond...
US FDA pushes decision on Moderna's RSV vaccine to end of this month
Reuters· 4 days ago, opens new tab respiratory syncytial virus (RSV) vaccine due to "administrative constraints" and...
Moderna says FDA delaying decision on RSV vaccine approval
Stars and Stripes· 4 days agoUS regulators’ decision on whether to approve Moderna Inc.’s vaccine for RSV has been delayed due to...
Midday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall By Investing.com
Investing.com· 4 days agoMidday movers: Novavax, Nvidia, Sweetgreen rise; Moderna, Yelp fall
FDA delays decision date for Moderna's RSV vaccine - Boston Business Journal
The Business Journals· 4 days agoJust days before its deadline, the U.S. Food and Drug Administration says it's giving itself more...
Moderna says FDA delaying decision on RSV vaccine approval, shares fall
Investing.com· 4 days agoModerna says FDA delaying decision on RSV vaccine approval, shares fall
What's Going With Moderna Stock On Friday? - Moderna (NASDAQ:MRNA)
Benzinga· 4 days agoThe Food and Drug Administration (FDA) notified Moderna Inc MRNA on Friday that its review of a new vaccine has been delayed. The agency, citing administrative constraints ...